All In Biotech

NDA 019781 · Acertis Pharms

Prometrium

Progesterone · Oral · Progesterone

Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

May 14, 1998

Approved uses

1

Original approval plus efficacy supplements

Registered trials

897

206 Phase 3, 84 recruiting

FAERS reports

23,055

12,952 serious, 504 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 23, 2026.

INDICATIONS AND USAGE PROMETRIUM ® (progesterone, USP) Capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • PROMETRIUM · PROGESTERONE 300MG · CAPSULE, ORAL · Discontinued
  • PROMETRIUM · PROGESTERONE 100MG · CAPSULE, ORAL · Prescription · TE AB
  • PROMETRIUM · PROGESTERONE 200MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Progesterone" as an intervention, any sponsor and status, largest first.

All 897 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache2,101
  • fatigue1,832
  • off label use1,831
  • drug ineffective1,821
  • nausea1,506
  • pain1,466
  • rash976
  • dizziness965
  • exposure during pregnancy925
  • foetal exposure during pregnancy921
  • hypersensitivity858
  • diarrhoea850

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004227
2005300
2006275
2007243
2008316
2009430
2010532
2011426
2012613
2013507
2014548
2015980
20161,372
20171,087
20181,152
20191,329
20201,386
20211,312
20221,480
20231,687
20242,061
20252,261
20262,531

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Prometrium (Progesterone, Micronized)

2024 spending

$1.0M

Beneficiaries

304

1,031 claims

Per beneficiary

$3,395

$17.69 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$277,204
2024$1,031,956

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,179 on PubMed

Sponsor: Acertis Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.